Tirzepatide (Mounjaro) — what it does, evidence, and safety

What it is

Tirzepatide is best known as the medicine behind Mounjaro and Zepbound — a lab-made peptide that activates two gut-hormone receptors at once (GLP-1 and GIP, a 'dual agonist') to increase fullness and help control blood sugar. It's FDA-approved as a prescription medicine: Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea with obesity, given as a once-weekly injection under the skin.

What the research found

Tirzepatide (Mounjaro, Zepbound) is a weekly GIP/GLP-1 injection FDA-approved for type 2 diabetes and weight management. In the pivotal obesity trial (SURMOUNT-1) it was associated with average weight reductions of about 15% to 21% across doses over 72 weeks versus about 3% on placebo, and in a head-to-head diabetes trial (SURPASS-2) it produced greater blood-sugar (HbA1c) reduction and greater weight loss than semaglutide. Nausea was the most common dose-limiting side effect. The research attributes these weight and blood-sugar changes largely to reduced appetite and food intake (greater satiety via the gut-hormone pathway these agents act on), an appetite and energy-intake mechanism measured across the trials.

Status and regulatory position

FDA approved (Mounjaro for T2D in adults, 2022; Zepbound for chronic weight management in adults, 2023; Zepbound for moderate-to-severe obstructive sleep apnea with obesity in adults, 2024; Mounjaro for pediatric T2D in patients ≥10 years, December 2025 — SUPPL-39 to NDA 215866, based on SURPASS-PEDS Phase 3 trial). No cardiovascular, heart-failure, or liver indication has been approved as of 2026-07-18: the heart-failure-with-preserved-ejection-fraction plus obesity submission (based on the SUMMIT trial) was filed with FDA and EMA in 2025 and remains under review awaiting a decision; MASH remains at phase 2 (SYNERGY-NASH) with no approval and no filing.

Safety

Tirzepatide is a prescription-only medication and carries a class boxed warning related to thyroid C-cell tumors. It is not on the WADA Prohibited List. VialWise is a research and educational reference, not medical advice — consult a licensed professional.

Disclosures

⚠️ For research and educational purposes only. Tirzepatide is FDA approved under two brand names (Mounjaro for type 2 diabetes; Zepbound for chronic weight management and obstructive sleep apnea with obesity). Information in this entry is informational, not medical advice. Always confirm dose calculations with the in-app calculator and consult appropriate professional guidance before any protocol decisions.

⚠️ Precision matters at low doses. Small dosing errors that look trivial in absolute terms can be significant in percentage terms when starting doses are small. A one-unit mis-draw at a 5-unit dose is a 20% error; the same one-unit error at a 50-unit dose is only 2%. Tirzepatide's starting dose typically lands depending on reconstitution. Always verify draws against the in-app calculator and double-check the unit count on the syringe before injecting — most acutely at the smallest draws in your titration.

Quick reference

Common vial sizes	(research/compounded); branded products are pen-only per dose
Frequency	Once weekly subcutaneous
Half-life	~5 days (~117 hours), enabled by C20 fatty di-acid albumin-binding moiety[⁵]
Route	Subcutaneous
Onset of action	Appetite suppression typically reported within the first week of dosing; meaningful weight change observed by week 8–12 in trials; full effect generally observed at maximum tolerated dose by week 20–24

In depth

Tirzepatide is a single-molecule dual agonist at the GLP-1 and GIP receptors, developed by Eli Lilly and marketed under two brand names: Mounjaro (subcutaneous, type 2 diabetes, FDA approved May 2022 for adults; expanded to include patients ≥10 years of age in December 2025 — SUPPL-39 to NDA 215866, based on the SURPASS-PEDS Phase 3 trial)[⁸] and Zepbound (subcutaneous, chronic weight management approved November 2023; expanded to include moderate-to-severe obstructive sleep apnea with obesity in December 2024). It sits between semaglutide (single-receptor GLP-1 agonist) and retatrutide (triple GLP-1/GIP/glucagon agonist) in the receptor-engineering progression of the incretin class.

Mechanistically, tirzepatide is a 39-amino-acid peptide engineered with a C20 fatty di-acid moiety for albumin binding, which extends its half-life to approximately 5 days and supports once-weekly dosing.[⁵] The dual mechanism means GLP-1 receptor activation drives glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways; GIP receptor activation enhances insulin secretion further and contributes additional weight-loss and metabolic effects that monotherapy GLP-1 agonists do not produce. The molecule has been shown to be biased toward the GIP receptor relative to native GIP, and to produce a less potent but functional response at the GLP-1 receptor relative to native GLP-1.[⁵]

The pivotal obesity trial (SURMOUNT-1; Jastreboff et al., NEJM 2022; n=2,539) reported least-squares mean weight reductions, after 72 weeks, of −15.0%, −19.5%, and −20.9%, compared with −3.1% in the placebo arm.[¹] In type 2 diabetes, the head-to-head SURPASS-2 trial (Frias et al., NEJM 2021; n=1,879) directly compared tirzepatide weekly against semaglutide weekly and reported greater HbA1c reductions and greater weight loss across all tirzepatide doses, with the dose producing approximately 2.0% greater HbA1c reduction and approximately 5–7 kg greater weight loss than semaglutide.[²]

Tirzepatide differs from the other GLP-1 family members covered in this library in three respects worth flagging for researchers comparing them: (1) it occupies the middle ground in absolute weight loss between semaglutide (~15%) and retatrutide (~24% in phase 2); (2) it is the only member with FDA-approved indications spanning T2D, obesity, and obstructive sleep apnea; and (3) it is the member with the most published direct head-to-head trial data against another modern GLP-1 agonist — two such trials, not one: SURPASS-2 (tirzepatide vs semaglutide weekly, in type 2 diabetes)[²] and SURMOUNT-5 (tirzepatide vs semaglutide, in obesity without diabetes).[¹²] Earlier versions of this entry described SURPASS-2 as the only published head-to-head; SURMOUNT-5, published in 2025, makes it the second, and the caveat matters when comparing this entry against older secondary write-ups that still repeat the single-trial framing.

Cardiovascular, heart-failure, and liver research — investigational status. In SURPASS-CVOT, a cardiovascular-outcomes trial in adults with type 2 diabetes and atherosclerotic cardiovascular disease (n≈13,299), tirzepatide was reported as non-inferior to dulaglutide for major adverse cardiovascular events (hazard ratio 0.92, 95.3% CI 0.83–1.01).[⁹] A post-hoc cardiorenal analysis of the same trial has also been published.[¹⁰] In SUMMIT, a trial in participants with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide reduced a composite of worsening heart-failure events and cardiovascular death relative to placebo.[¹¹] In SYNERGY-NASH, a phase 2 trial in metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis, tirzepatide was associated with higher rates of MASH resolution than placebo.[¹³] None of these are approved indications. The HFpEF-with-obesity submission based on SUMMIT was filed with the FDA and EMA in 2025 and remains under review as of this writing; MASH remains investigational at phase 2 with a phase-3 program ongoing. These results are reported here as trial findings, not as expected outcomes for any individual, and tirzepatide should not be characterized as a cardiovascular, heart-failure, or liver therapy.

Reported side effects

Commonly reported

Nausea — most common dose-limiting side effect, typically dose-dependent and most pronounced during titration steps
Vomiting
Diarrhea
Constipation
Decreased appetite (often reported as a benefit; extreme cases warrant dose reduction)
Dyspepsia / abdominal discomfort
Fatigue
Injection site reactions
Anhedonia and mood flattening (reported across the incretin class)
Headache
Hypoglycemia (uncommon as monotherapy; more common when combined with insulin or sulfonylureas in T2D contexts)

Serious

Severe persistent vomiting or signs of dehydration
Acute pancreatitis symptoms (severe abdominal pain radiating to back)
Gallbladder symptoms (right upper quadrant pain, jaundice) — gallstones and cholecystitis reported at elevated rates in tirzepatide trials, similar to other incretins
Acute kidney injury (typically secondary to dehydration from GI side effects)
Diabetic retinopathy worsening (observed in T2D contexts, especially when adding tirzepatide on top of existing diabetes therapy)
Severe hypersensitivity reactions
Suicidal ideation or new-onset mood changes (under regulatory review across the incretin class as of 2024–2025)

Contraindications and warnings

Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — FDA-mandated boxed warning across the incretin class, based on rodent thyroid C-cell tumor findings; human relevance is debated but the warning is legally binding for prescribers in the US

History of pancreatitis

Severe gastrointestinal disease (gastroparesis especially — tirzepatide further slows gastric emptying)

Severe renal impairment (limited data; dehydration risk amplifies)

Concurrent use of other GLP-1, GIP, or glucagon receptor agonists

Pregnancy and lactation: not recommended. Animal studies showed reproductive toxicity; the Mounjaro and Zepbound labels recommend discontinuation at least 2 months before a planned pregnancy due to the long half-life

Key terms

GLP-1 receptor agonist: A compound that switches on the GLP-1 receptor, the same target a natural gut hormone uses to signal fullness and help regulate blood sugar.
GIP receptor: A gut-hormone receptor that, like GLP-1, enhances insulin release and contributes to metabolic and weight effects.
Dual agonist: A compound that activates two different receptors at once (for example, the GLP-1 and glucagon receptors).
Subcutaneous: An injection into the fatty layer just under the skin, rather than into a muscle or vein.
Titration: Starting at a low dose and increasing it gradually.

Sources

Related entries

CJC-1295 / Ipamorelin Blend — discussed together in this entry's stacks section
BPC-157 / TB-500 Blend — discussed together in this entry's stacks section
Tesamorelin — discussed together in this entry's stacks section
Amycretin — same mechanism class
CagriSema — same mechanism class
Dulaglutide — same mechanism class